Immuno-Oncology 360° Agenda 2026 Page

Theresa LaVallee, PhD, Chief Scientific & Development Officer, Coherus Oncology

9:00AM - 9:25AM

Keynote: Checkpoint Blockade and Beyond: Charting the Next Era of Immuno-Oncology

Keynote Speaker:

Jedd Wolchok, MD, PhD, Meyer Director of the Sandra and Edward Meyer Cancer Center and Professor of Medicine, Weill Cornell Medicine

Showing Events in 1 Track from 09:25am to 09:45am

New Technologies in Transformational Biology

9:25AM - 9:45AM

Beyond Cytotoxicity: Granzyme B ADCs – A New Paradigm in Immuno-Oncology Payload Discovery

Claire Thuning-Roberson, PhD, CEO, AbBC Therapies

Showing Events in 1 Track from 09:45am to 10:25am

Grand Opening of the IO360° Networking Café
Grand Ballroom Foyer

9:45AM - 10:25AM

Grand Opening of the IO360° Networking Café

Showing Events in 1 Track from 10:25am to 11:20am

New Technologies in Transformational Biology (Continued)
Grand Ballroom

Plenary Chair:

James Gulley, MD, PhD, FACP, Co-Director, Center for Immuno-Oncology, CCR & Clinical Director, National Cancer Institute, NIH

10:25AM - 10:45AM

AstraZeneca’s Bet on In Vivo CAR-T: A Preclinical Perspective

Philippe Parone, PhD, Head, Cell Therapy In Vivo / CSO, AstraZeneca / EsoBiotec

10:45AM - 11:05AM

Antisense Oligonucleotides (ASOs) for Cancer: Why This Modality’s Moment Has Arrived

Zdravka Medarova, PhD, CSO & Co-founder, TransCode Therapeutics

11:05AM - 11:20AM

Unlocking New Dimensions in Immuno-Oncology Research with Real-Time Imaging Spectral Flow Cytometry

Scott Bornheimer, PhD, Director, Medical & Scientific Affairs, BD Biosciences

Showing Events in 1 Track from 11:20am to 11:30am

10 Min Health Break

11:20AM - 11:30AM

10 Min Health Break

Showing Events in 1 Track from 11:30am to 12:20pm

Morning Tracks

11:30AM - 12:20PM

Two Track Choices: IO Novel Technologies Showcase

Participating Companies:

Showing Events in 2 Tracks from 11:30am to 12:20pm

TRACK 1: IO Novel Tech Showcase A
Grand Ballroom

Track Chair:

Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics

11:30AM - 11:40AM

Picture Health

Brian Kelly, Chief Commercial Officer, Picture Health

11:40AM - 11:50AM

RareCyte

Jeff Chamberlain, PhD, Director, Biopharma Partnerships, RareCyte

11:50AM - 12:00PM

Ozette Technologies, Inc

Mike Comeau, Director, Scientific Alliances, Ozette Technologies, Inc.

12:00PM - 12:10PM

BobcatBio, Inc

Stephen Rocamboli, CEO, BobcatBio, Inc.

12:10PM - 12:20PM

Radiomics

Wim Vos, PhD, CEO, Radiomics.bio

TRACK 2: IO Novel Tech Showcase B
Constitution Ballroom AB

Track Chair:

Pavel Khrimian, MBA, Co-Founder, Chief Business Officer, Deka Biosciences

11:30AM - 11:40AM

TD2 Oncology

Jennifer Stewart, PhD, VP, Flow Cytometry Strategy, TD2

11:40AM - 11:50AM

RoukenBio

Matt Freer, Senior BD Manager, RoukenBio

11:50AM - 12:00PM

GenoBioTX

Derek Reznik, PhD, BD Manager, GenoBioTX

12:00PM - 12:10PM

OrgaNova | TRiCBiO

Michael Duffy, PhD, BD Director, OrgaNova | TRiCBiO

12:10PM - 12:20PM

Alithea Biotechnology GmbH

Tim Fugmann, PhD, CSO and Co-Founder, Alithea Biotechnology GmbH

Showing Events in 2 Tracks from 12:20pm to 01:35pm

Lunch and Networking
Networking & Exhibits: Grand Ballroom Foyer / 1:1 Partnering Meetings: Back Bay AB

12:20PM - 1:35PM

Lunch & 1:1 Partnering Meetings Begin

Women's Luncheon
Republic Ballroom

12:20PM - 1:35PM

3rd Annual Women Leaders in IO Panel & Luncheon

Marisa Dolled-Filhart, PhD, Global Team Lead, Early Oncology; Asset and Portfolio Management, Daiichi Sankyo US

Jacqueline Karmel, Chair, imCORE Executive Office & Principal International Scientific Director, Cancer Immunotherapy, Roche

Theresa LaVallee, PhD, Chief Scientific & Development Officer, Coherus Oncology

Julie Martin, MSc, MBA, President & CEO, Scimega Research

Barbra Sasu, PhD, CSO, Dispatch Bio

Showing Events in 2 Tracks from 01:40pm to 03:20pm

TRACK 1: New Tech in Transformational Biology
Grand Ballroom

Track Chair:

Julie Bailis, PhD, Vice President, Oncology Research, Amgen

1:40PM - 2:05PM

AI-Driven Protein Design: The Next Frontier in TCR-Based Immuno-Oncology

John Connolly, PhD, CSO, Parker Institute for Cancer Immunotherapy (PICI)

2:05PM - 2:30PM

Next-Generation Cancer Vaccines: Mining the Dark Genome for Novel Shared Antigens

Jon Moore, PhD, CSO, Epitopea

2:30PM - 2:55PM

AI-driven Discovery of Novel CAR T Cells as a Multi-cancer Therapy

Daniel Baker, PhD, Scientist, June Lab University of Pennsylvania

2:55PM - 3:20PM

CAR-DCs to Improve Antitumor Immunity

Carl DeSelm, MD, PhD, Assistant Professor, Radiation Oncology & Principle Investigator, Washington University in St. Louis

TRACK 2: Imaging-Driven Innovation in IO
Constitution Ballroom AB

Track Chair:

Jayant Narang, MD, Sr Medical Director, Clinical Oncology Imaging Lead, Preclinical and Translational Sciences, Takeda Pharmaceuticals

1:40PM - 2:00PM

The Imaging Reality Check: Practical Insights from a Leading IO Trialist

Diwakar Davar, MD, Associate Professor, Clinical Director, Melanoma and Skin Cancer Program, UPMC Hillman Cancer Center

2:00PM - 2:40PM

Panel: Imaging Lessons from IO 1.0 to Shape IO 2.0: From Smarter Design to Meaningful Impact

Antonio "Tito" Fojo, MD, Professor of Medicine / Co-Director, Columbia Adrenal Surgery Center, Columbia University Medical Center

Susan E. Bates, MD, Professor of Medicine / Director, Translational Cancer Medicine, Columbia University Medical Center

Cynthia Goldberg, MD, Executive Director, Head of Clinical Imaging MRL, GCTO, Merck Research Laboratories

Gordon Harris, PhD, Chief Scientific Officer/Director, Tumor Imaging Metrics Core, Yunu/Dana Farber Harvard Cancer Center

Jack Hoppin, PhD, Chairman, Chief Executive Officer, Ratio Therapeutics

David Leung, MD, PhD, Head of Imaging, Daiichi Sankyo

2:40PM - 3:20PM

Panel: Measuring What Matters: Using Biomarkers to Guide Patient Selection and Treatment in IO

Ryan Hartmaier, PhD, Sr Director, Translational Medicine, Oncology R&D, AstraZeneca

Gregory Frank, PhD, Global Scientific Partnering Strategy, Immuno-Oncology, GE HealthCare

Greg Goldmacher, MD, PhD, MBA, Associate VP, Clinical Research; Head, Clinical Imaging & Pathology, Merck Research Laboratories

Catherine Hines, PhD, GI Oncology Imaging Lead, GSK

Dejan Knezevic, PhD, Senior Director, Bio Pharma Business Development, Natera

Showing Events in 1 Track from 03:25pm to 04:05pm

Afternoon Networking Break
Networking & Exhibits: Grand Ballroom Foyer / 1:1 Partnering Meetings: Back Bay AB

3:25PM - 4:05PM

Afternoon Networking Break and Partnering Meetings

Showing Events in 2 Tracks from 04:10pm to 05:40pm

TRACK 1: Breakthroughs in Translational Science Part 1
Grand Ballroom

Track Chair:

Zhen Su, MD, MBA, CEO & Director, Marengo Therapeutics

4:10PM - 4:30PM

RIPTAC: A New Frontier in Targeted Protein Degradation – Insights from J&J

Charles Drake, MD, PhD, VP, Immuno-Oncology, J&J Innovative Medicine

4:30PM - 4:50PM

What Drives an Effective Anti-Tumor Immune Response? Insights from Blood-Borne and Solid Tumors

Erik Manting, PhD, CEO, Mendus

4:50PM - 5:10PM

Targeting IL-27 to Activate Antitumor Immunity: Insights from Casdozokitug

Sruthi Ravindranathan, PhD, Senior Scientist, Translational Medicine, Coherus Oncology

5:10PM - 5:30PM

Learnings from VG161: Reprogramming Immunity Through Oncolytic Virotherapy

William Jia, PhD, CSO & Co-founder, Virogin Biotech

TRACK 2: Imaging-Driven Innovation in IO
Constitution Ballroom AB

Track Chair:

Jack Hoppin, PhD, Chairman, Chief Executive Officer, Ratio Therapeutics

4:10PM - 4:30PM

Understanding, Detecting and Harnessing Immunogenic Cell Death in IO

Lorenzo Galluzzi, PhD, Associate Professor Cancer Signaling and Microenvironment Research Program, Fox Chase Cancer Center, Temple Health

4:30PM - 5:10PM

Panel - From Hype to Impact: Where AI in Imaging Is Moving the Needle in IO Development

Greg Goldmacher, MD, PhD, MBA, Associate VP, Clinical Research; Head, Clinical Imaging & Pathology, Merck Research Laboratories